The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B.
 
Go Saito
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Ryo Ko
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; MSD
 
Yuki Shiko
No Relationships to Disclose
 
Yoshiaki Nagai
No Relationships to Disclose
 
Risa Ebina-Shibuya
No Relationships to Disclose
 
Kazutoshi Isobe
No Relationships to Disclose
 
Kazuhiro Nishiyama
No Relationships to Disclose
 
Hiroshi Wakui
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; UCB
 
Yuta Takashima
No Relationships to Disclose
 
Kei Sonehara
No Relationships to Disclose
 
Shoko Shimamura
No Relationships to Disclose
 
Kyoichi Kaira
No Relationships to Disclose
 
Yoshiro Nakahara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - JSPS KAKENHI; The Japan Lung Cancer Society
 
Hironori Ashinuma
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; Lilly; Merck; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Takeda
 
Hiromi Nagashima
No Relationships to Disclose
 
Yohei Suzuki
No Relationships to Disclose
 
Kei Chubachi
No Relationships to Disclose
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Lilly; Merck Sharp and Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma; Janssen (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kunihiko Kobayashi
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Speakers' Bureau - AstraZeneca
Research Funding - Zeria Pharmaceutical Co. (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on Japanese patent # 7422498; Peptide of inhibiting cell migration, cell invasion, and cancer metastasis.
 
Takehito Shukuya
Honoraria - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma; MSD; Novartis